Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YH1
- Development stage
- Phase 3
- Lead developer
- Chang Gung Memorial Hospital
- Administration
- Oral
01
Overview
YH1 is an investigational oral concentrated traditional Chinese herbal-extract granule formula developed for type 2 diabetes mellitus. It contains equal proportions of **Rhizoma Coptidis** and **Shen-Ling-Bai-Zhu-San**, a multi-herb traditional formula. In a randomized, double-blind, placebo-controlled Phase 2 pilot trial, YH1 was administered as an add-on to stable oral hypoglycemic therapy in patients with poorly controlled type 2 diabetes; a subsequent small observational study examined associations between YH1 treatment, glycemic and lipid measures, gut microbiota, and bile-acid profiles. Its precise molecular targets and clinically validated mechanism of action have not been established. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6695147/))
- Other names
- YH1 herbal granulesYH-1 herbal granulesYH 1 herbal granules
Beyond the preview
Go deeper on YH1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YH1.